46 related articles for article (PubMed ID: 10426152)
1. The importance of HLA DRB1 gene allele to clinical features and disability in patients with multiple sclerosis in Lithuania.
Balnyte R; Rastenyte D; Vaitkus A; Mickeviciene D; Skrodeniene E; Vitkauskiene A; Uloziene I
BMC Neurol; 2013 Jul; 13():77. PubMed ID: 23837503
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021.
Watson C; Thirumalai D; Barlev A; Jones E; Bogdanovich S; Kresa-Reahl K
Neurol Ther; 2023 Dec; 12(6):1961-1979. PubMed ID: 37682512
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.
Müller S; Heidler T; Fuchs A; Pfaff A; Ernst K; Ladinek G; Wilke T
Neurol Ther; 2020 Jun; 9(1):67-83. PubMed ID: 31832974
[TBL] [Abstract][Full Text] [Related]
4. Whole-Genome DNA Methylation Analysis of Peripheral Blood Mononuclear Cells in Multiple Sclerosis Patients with Different Disease Courses.
Kulakova OG; Kabilov MR; Danilova LV; Popova EV; Baturina OA; Tsareva EY; Baulina NM; Kiselev IS; Boyko AN; Favorov AV; Favorova OO; Vlassov VV
Acta Naturae; 2016; 8(3):103-110. PubMed ID: 27795849
[TBL] [Abstract][Full Text] [Related]
5. Essential trace element levels in multiple sclerosis: Bridging demographic and clinical gaps, assessing the need for supplementation.
Stojsavljević A; Jagodić J; Pavlović S; Dinčić E; Kuveljić J; Manojlović D; Živković M
J Trace Elem Med Biol; 2024 May; 83():127421. PubMed ID: 38452433
[TBL] [Abstract][Full Text] [Related]
6. [DNA Methylation Profile of CD14+ Monocytes Changes in Primary Progressive Multiple Sclerosis].
Kiselev IS; Kulakova OG; Baturina OA; Kabilov MR; Boyko AN; Favorova OO
Mol Biol (Mosk); 2023; 57(5):819-826. PubMed ID: 37752647
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis.
Khan F; Amatya B; Turner-Stokes L
Neurol Res Int; 2011; 2011():740505. PubMed ID: 22013521
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of safety of rituximab in patients with multiple sclerosis: A retrograde study.
Majdinasab N; Sadrian M; Kashipazha D; Moradi M
Curr J Neurol; 2020 Jul; 19(3):103-106. PubMed ID: 38011421
[No Abstract] [Full Text] [Related]
9. Medical history risk factors in primary progressive multiple sclerosis: A case-control study.
Maroufi H; Moghadasi AN; Rezaei-Aliabadi H; Sahraian MA; Eskandarieh S
Curr J Neurol; 2021 Apr; 20(2):86-94. PubMed ID: 38011391
[No Abstract] [Full Text] [Related]
10. Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients.
Mokhtari S; Houshi S; Mirmosayyeb O; Barzegar M; Afshari-Safavi A; Ghasemi M; Shaygannejad V
Int J Prev Med; 2023; 14():86. PubMed ID: 37854985
[TBL] [Abstract][Full Text] [Related]
11. A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis.
Field J; Browning SR; Johnson LJ; Danoy P; Varney MD; Tait BD; Gandhi KS; Charlesworth JC; Heard RN; ; Stewart GJ; Kilpatrick TJ; Foote SJ; Bahlo M; Butzkueven H; Wiley J; Booth DR; Taylor BV; Brown MA; Rubio JP; Stankovich J
PLoS One; 2010 Oct; 5(10):e13454. PubMed ID: 21049023
[TBL] [Abstract][Full Text] [Related]
12. The immunogenetics of multiple sclerosis.
Svejgaard A
Immunogenetics; 2008 Jun; 60(6):275-86. PubMed ID: 18461312
[TBL] [Abstract][Full Text] [Related]
13. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.
DeLuca GC; Ramagopalan SV; Herrera BM; Dyment DA; Lincoln MR; Montpetit A; Pugliatti M; Barnardo MC; Risch NJ; Sadovnick AD; Chao M; Sotgiu S; Hudson TJ; Ebers GC
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20896-901. PubMed ID: 18087043
[TBL] [Abstract][Full Text] [Related]
14. Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland.
McGuigan C; Dunne C; Crowley J; Hagan R; Rooney G; Lawlor E; Hutchinson M
J Neurol; 2005 Oct; 252(10):1245-8. PubMed ID: 16158194
[TBL] [Abstract][Full Text] [Related]
15. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis.
Greer JM; Pender MP
J Neurol Neurosurg Psychiatry; 2005 May; 76(5):656-62. PubMed ID: 15834022
[TBL] [Abstract][Full Text] [Related]
16. Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis.
Rubio JP; Bahlo M; Butzkueven H; van Der Mei IA; Sale MM; Dickinson JL; Groom P; Johnson LJ; Simmons RD; Tait B; Varney M; Taylor B; Dwyer T; Williamson R; Gough NM; Kilpatrick TJ; Speed TP; Foote SJ
Am J Hum Genet; 2002 May; 70(5):1125-37. PubMed ID: 11923913
[TBL] [Abstract][Full Text] [Related]
17. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.
Hensiek AE; Sawcer SJ; Feakes R; Deans J; Mander A; Akesson E; Roxburgh R; Coraddu F; Smith S; Compston DA
J Neurol Neurosurg Psychiatry; 2002 Feb; 72(2):184-7. PubMed ID: 11796767
[TBL] [Abstract][Full Text] [Related]
18. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis.
McDonnell GV; Mawhinney H; Graham CA; Hawkins SA; Middleton D
J Neurol Sci; 1999 May; 165(1):77-83. PubMed ID: 10426152
[TBL] [Abstract][Full Text] [Related]
19. Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis.
McDonnell GV; Kirk CW; Middleton D; Droogan AG; Hawkins SA; Patterson CC; Graham CA
J Neurol; 1999 Nov; 246(11):1051-8. PubMed ID: 10631637
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
